Media coverage about argenx (NASDAQ:ARGX) has been trending somewhat negative this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. argenx earned a coverage optimism score of -0.01 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.5176796456059 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s analysis:
- Zacks: Analysts Anticipate argenx SE – (ARGX) Will Post Quarterly Sales of $6.35 Million (americanbankingnews.com)
- Zacks: Analysts Expect argenx SE – (ARGX) Will Post Earnings of -$0.59 Per Share (americanbankingnews.com)
- Argenx receives feedback on Phase 3 clinical trial for efgartigimod in generalized myasthenia gravis (seekingalpha.com)
- argenx receives feedback from Japan’s PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis (finance.yahoo.com)
Shares of ARGX traded up $0.17 during mid-day trading on Friday, reaching $93.83. The company’s stock had a trading volume of 64,500 shares, compared to its average volume of 137,129. The firm has a market capitalization of $2.95 billion, a P/E ratio of -66.66 and a beta of 2.42. argenx has a 1 year low of $20.50 and a 1 year high of $103.00.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Further Reading: What does earnings per share mean?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.